



ASX / MEDIA RELEASE

5th November 2015

Senior Executive Departure

Sydney, Australia; 5th November 2015 – Sirtex Medical Limited (ASX:SRX) wishes to advise that Dr Burwood Chew, Chief Executive – Asia Pacific will depart the Company, effective immediately.

We take this opportunity to thank Dr Chew for his contribution to the Company and to extend our best wishes to him for the future.

Mr Nigel Lange, Chief Executive – EMEA, has assumed overall management responsibility for the Asia Pacific business, pending the appointment of a suitable replacement. Sirtex will advise the market accordingly once this process has been completed.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. To date, more than 55,000 doses have been supplied to treat patients with liver cancer at more than 900 medical centres in over 40 countries worldwide. Please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Mr Gilman Wong
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406